Cooley advised Medicxi and other venture capital investors in Sanofi’s $1.6 billion acquisition of Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections. Vicebio shareholders will receive up to a total of $1.6 billion, including an upfront payment of $1.15 billion and development and regulatory milestones payments of $450 million.